Steroidogenic acute regulatory protein molecular weight

In humans, the CYP17A1 gene is largely associated with endocrine effects and steroid hormone metabolism. [21] [22] [23] Furthermore, mutations in the CYP17A1 gene are associated with rare forms of congenital adrenal hyperplasia, in particular 17α-hydroxylase deficiency/17,20-lyase deficiency and isolated 17,20-lyase deficiency. Overall, CYP17A1 is an important target for inhibition in the treatment of prostate cancer because it produces androgen that is required for tumor cell growth. [24] [25] Currently, the FDA has approved only one CYP17A1 inhibitor, abiraterone, which contains a steroidal scaffold that is similar to the endogenous CYP17A1 substrates. Abiraterone is structurally similar to the substrates of other cytochrome P450 enzymes involved in steroidogenesis, and interference can pose a liability in terms of side effects. Using nonsteroidal scaffolds is expected to enable the design of compounds that interact more selectively with CYP17A1. [25] Potent inhibitors of the CYP17A1 enzyme provide a last line defense against ectopic androgenesis in advanced prostate cancer. [26]

Steroidogenic acute regulatory protein molecular weight

steroidogenic acute regulatory protein molecular weight

Media:

steroidogenic acute regulatory protein molecular weightsteroidogenic acute regulatory protein molecular weightsteroidogenic acute regulatory protein molecular weightsteroidogenic acute regulatory protein molecular weightsteroidogenic acute regulatory protein molecular weight

http://buy-steroids.org